HeyJaredM. Alexander Otto
- Indexed articles, last 90 days
- 20
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 15, 2026
Latest articles
Pancreatic Cancer: Is SBRT or ChemoRT Better Before Surgery? (opens the original)
Read excerpt
BOSTON — What type of neoadjuvant therapy is best for patients with resectable, borderline, or locally advanced pancreatic ductal adenocarcinoma (PDAC)? While neoadjuvant therapy has become more common, the optimal type and duration of treatment remain unclear, explained William Hall, MD, radiation oncologist at the Medical College of Wisconsin in Milwaukee. To bridge this gap, Hall and colleagues compared two commonly used approaches — stereotactic body radiotherapy (SBRT) and conventionally fr
SBRT Matches Prostatectomy, With Fewer Side Effects (opens the original)
Read excerpt
BOSTON — Stereotactic body radiotherapy (SBRT) and radical prostatectomy provide comparable long-term control of localized prostate cancer, but radiotherapy comes with far fewer urinary and sexual problems, according to the first phase 3 randomized trial to directly compare the two options. Based on results from 123 UK men randomly assigned to either approach in the PACE-A trial, the 8-year Kaplan-Meier estimate of freedom from biochemical or clinical failure was 91% with SBRT and 84% with prost
Will Fractionated Radiation Become SOC for Brain Metastases? (opens the original)
Read excerpt
BOSTON — Giving fractionated stereotactic radiosurgery (SRS) instead of single-fraction SRS to those with resection of large brain metastases reduces cancer recurrence, shows the first randomized trial to compare the two options head-to-head. After resection of one brain metastasis > 2 cm across, 1-year surgical bed control was 87% among 120 patients randomly assigned to three to five fractions of SRS compared with 81% among 122 patients assigned to single-fraction SRS treatment. Patients receiv
Belzutifan Plus Lenvatinib Approved for Advanced ccRCC (opens the original)
Read excerpt
The FDA has approved belzutifan (WELIREG, Merck) in combination with lenvatinib (Lenvima, Eisai) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) who have received a PD-1 or a PD-L1 inhibitor. This marks the third ccRCC approval for the hypoxia-inducible factor-2-alpha inhibitor belzutifan. Its previous approvals were for adjuvant ccRCC treatment with pembrolizumab and as monotherapy for advanced ccRCC after both a PD-1 or PD-L1 inhibitor and a VEGF TKI. Lenvatin
New ASTRO Guidelines Focus on Radiation for Bladder Cancer (opens the original)
Read excerpt
The American Society for Radiation Oncology (ASTRO) has released its first guidelines focused specifically on the use of radiation for bladder cancer. Like other medical organizations, ASTRO supports trimodal therapy (TMT) — maximal transurethral tumor resection followed by chemoradiation — as a curative alternative to cystectomy for muscle-invasive bladder cancer for select patients. The guidelines fill in the details for various TMT scenarios, but the advice extends well beyond bladder preserv
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.